Adam Crystal sold $736k of TNGX
President, R&D at Tango Therapeutics, Inc.. 27,000 shares at an average of $27.24, traded Aug 3, 2026, filed Aug 5, 2026.
Score components
- +20RolePresident
- +21Trade size$736k at market
- +5Share of holdings soldSold 19% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-335002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 3, 2026 | MOption exercise Common Stock10b5-1 | +27,000 | $5.20 | $140k | 142,743 | Aug 5, 2026 |
| Aug 3, 2026 | SOpen-market sale Common Stock10b5-1 | -5,267 | $26.79 | $141k | 137,476 | Aug 5, 2026 |
| Aug 3, 2026 | SOpen-market sale Common Stock10b5-1 | -21,733 | $27.35 | $594k | 115,743 | Aug 5, 2026 |
| Aug 3, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -27,000 | $0.00 | $0 | 287,040 | Aug 5, 2026 |
Related signals
Other insiders at Tango Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 18Weak | Tango Therapeutics, Inc. | Adam Crystal President, R&D | $661k 27,000 shares | -19% | |
| 20Weak | Tango Therapeutics, Inc. | Jessica Newcomb Principal Accounting Officer | $199k 8,200 shares | -12% | |
| 9Weak | Tango Therapeutics, Inc. | Adam Crystal President, R&D | $604k 27,000 shares | -19% | |
| 12Weak | Tango Therapeutics, Inc. | Adam Crystal President, R&D | $799k 27,000 shares | -19% | |
| 10Weak | Tango Therapeutics, Inc. | Adam Crystal President, R&D | $618k 27,000 shares | -19% | |
| 9Weak | Tango Therapeutics, Inc. | Adam Crystal President, R&D | $573k 27,000 shares | -19% | |
| 19Weak | Tango Therapeutics, Inc. | Adam Crystal President, R&D | $962k 38,460 shares | -25% | |
| 9Weak | Tango Therapeutics, Inc. | Adam Crystal President, R&D | $572k 27,000 shares | -19% | |
| 0Weak | Tango Therapeutics, Inc. | Adam Crystal President, R&D | $241k 12,000 shares | -10% | |
| 19Weak | Tango Therapeutics, Inc. | Adam Crystal President, R&D | $304k 20,251 shares | -15% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.